VAXCYTE, INC. Increase (Decrease) in Other Operating Assets
VAXCYTE, INC. (PCVX) reported Increase (Decrease) in Other Operating Assets of $69.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-05
- VAXCYTE, INC. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $52.95M, a 405.38% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $16.88M, a 157.49% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $11.54M, a 158.78% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $11.32M, a 63.41% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in other operating assets for fiscal 2025 was $39.89M, a 50.45% increase from fiscal 2024.
- VAXCYTE, INC. increase (decrease) in other operating assets for fiscal 2024 was $26.51M, a 19.68% decline from fiscal 2023.
- VAXCYTE, INC. increase (decrease) in other operating assets for fiscal 2023 was $33.01M, a 6998.28% increase from fiscal 2022.
- VAXCYTE, INC. increase (decrease) in other operating assets for fiscal 2022 was $465.00K, a 86.86% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $52.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $69.83M 10-Q · filed 2026-08-05 | $81.36M derived: sum of 3 quarters · filed 2026-08-05 | $92.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $16.88M 10-Q · filed 2026-05-06 | $28.41M derived: sum of 2 quarters · filed 2026-05-06 | $39.73M derived: sum of 3 quarters · filed 2026-05-06 | $50.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $11.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $22.86M derived: sum of 2 quarters · filed 2026-02-24 | $33.33M derived: sum of 3 quarters · filed 2026-08-05 | $39.89M 10-K · filed 2026-02-24 |
| 2025-09-30 | $11.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $21.79M derived: sum of 2 quarters · filed 2026-08-05 | $28.35M 10-Q · filed 2025-11-04 | $32.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $10.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $17.03M 10-Q · filed 2026-08-05 | $21.49M derived: sum of 3 quarters · filed 2026-08-05 | $28.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.55M 10-Q · filed 2026-05-06 | $11.01M derived: sum of 2 quarters · filed 2026-05-06 | $17.94M derived: sum of 3 quarters · filed 2026-05-06 | $24.48M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $11.38M derived: sum of 2 quarters · filed 2026-02-24 | $17.93M derived: sum of 3 quarters · filed 2026-02-24 | $26.51M 10-K · filed 2026-02-24 |
| 2024-09-30 | $6.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $13.47M derived: sum of 2 quarters · filed 2025-11-04 | $22.05M 10-Q · filed 2025-11-04 | $56.42M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $6.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $15.13M 10-Q · filed 2025-08-06 | $49.50M derived: sum of 3 quarters · filed 2026-02-24 | $49.21M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $8.58M 10-Q · filed 2025-05-07 | $42.95M derived: sum of 2 quarters · filed 2026-02-24 | $42.66M derived: sum of 3 quarters · filed 2026-02-24 | $42.20M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $34.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $34.08M derived: sum of 2 quarters · filed 2026-02-24 | $33.62M derived: sum of 3 quarters · filed 2026-02-24 | $33.01M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$286.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$748.00K derived: sum of 2 quarters · filed 2024-11-05 | -$1.36M 10-Q · filed 2024-11-05 | -$1.43M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$462.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.08M 10-Q · filed 2024-08-06 | -$1.15M derived: sum of 3 quarters · filed 2025-02-25 | -$1.95M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$615.00K 10-Q · filed 2024-05-08 | -$684.00K derived: sum of 2 quarters · filed 2025-02-25 | -$1.49M derived: sum of 3 quarters · filed 2025-02-25 | -$1.73M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$871.00K derived: sum of 2 quarters · filed 2025-02-25 | -$1.11M derived: sum of 3 quarters · filed 2025-02-25 | $465.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | -$802.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$1.04M derived: sum of 2 quarters · filed 2023-11-06 | $534.00K 10-Q · filed 2023-11-06 | $1.04M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$241.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.34M 10-Q · filed 2023-08-08 | $1.84M derived: sum of 3 quarters · filed 2024-02-27 | $4.92M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.58M 10-Q · filed 2023-05-08 | $2.09M derived: sum of 2 quarters · filed 2024-02-27 | $5.16M derived: sum of 3 quarters · filed 2024-02-27 | $4.67M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $509.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.58M derived: sum of 2 quarters · filed 2024-02-27 | $3.10M derived: sum of 3 quarters · filed 2024-02-27 | $3.54M 10-K · filed 2024-02-27 |
| 2021-09-30 | $3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $2.59M derived: sum of 2 quarters · filed 2022-11-07 | $3.03M 10-Q · filed 2022-11-07 | $3.14M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$485.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$44.00K 10-Q · filed 2022-08-08 | $64.00K derived: sum of 3 quarters · filed 2023-02-27 | $75.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $441.00K 10-Q · filed 2022-05-09 | $549.00K derived: sum of 2 quarters · filed 2023-02-27 | $560.00K derived: sum of 3 quarters · filed 2023-02-27 | $427.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $119.00K derived: sum of 2 quarters · filed 2023-02-27 | -$14.00K derived: sum of 3 quarters · filed 2023-02-27 | $75.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$122.00K derived: sum of 2 quarters · filed 2021-11-10 | -$33.00K 10-Q · filed 2021-11-10 | -$143.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$44.00K 10-Q · filed 2021-08-11 | -$154.00K derived: sum of 3 quarters · filed 2022-02-28 | -$286.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $89.00K 10-Q · filed 2021-05-11 | -$21.00K derived: sum of 2 quarters · filed 2022-02-28 | -$153.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$242.00K derived: sum of 2 quarters · filed 2022-02-28 | -$120.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$10.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $122.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $412.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |